Insmed (INSM) Q4 2024 earnings summary

Executive summary

• Achieved historic milestones in 2024, including positive Phase 3 ASPEN data for brensocatib in bronchiectasis and record ARIKAYCE revenues exceeding internal projections.

• Advanced multiple late-stage clinical programs: brensocatib, TPIP, and ARIKAYCE, with key readouts and regulatory filings on track or ahead of schedule.

• FDA accepted NDA for brensocatib in bronchiectasis with Priority Review; PDUFA date set for August 12, 2025.

• Ended 2024 with over $1.4 billion in cash, cash equivalents, and marketable securities, supporting ongoing investments and future launches.

Financial highlights

• 2024 global net revenue reached $363.7 million, up 19% year-over-year, surpassing guidance.

• U.S. ARIKAYCE revenue was $254.8 million (+14% YoY); Japan $87.7 million (+33% YoY); Europe/ROW $21.2 million (+39% YoY).

• Q4 2024 delivered the highest quarterly sales for ARIKAYCE in its history, with Q4 revenue of $104.4 million.

• Full-year 2024 net loss was $913.8 million ($5.57/share), up from $749.6 million ($5.34/share) in 2023, driven by increased R&D and SG&A expenses.

• Cost of product revenues for 2024 was $85.7 million (23.6% of revenues); R&D and SG&A expenses were $599 million and $462 million, respectively.

Outlook and guidance

• 2025 ARIKAYCE net revenue guidance: $405–$425 million, representing continued double-digit growth.

• Brensocatib U.S. launch expected in Q3 2025, with initial sales limited to a few weeks in Q3 due to mid-August PDUFA date, pending FDA approval.

• Phase 2 data for TPIP in PAH and brensocatib in CRS without nasal polyps expected in 2025; Phase 3 ENCORE trial for ARIKAYCE to read out in Q1 2026.